{"componentChunkName":"component---src-templates-chapter-level-2-chapter-level-2-tsx","path":"/topics/trichomoniasis/prescribing-information/tinidazole/","result":{"pageContext":{"chapter":{"id":"cdff86f4-ac12-56d7-b196-c5f9af1eb880","slug":"tinidazole","fullItemName":"Tinidazole","depth":2,"htmlHeader":"<!-- begin field 07a3e8fc-5756-4c0b-bdf2-e2af73340daa --><h2>Tinidazole</h2><!-- end field 07a3e8fc-5756-4c0b-bdf2-e2af73340daa -->","summary":"","htmlStringContent":"<!-- begin item 44ff4857-3302-4496-97b1-347a7f69a37a --><!-- end item 44ff4857-3302-4496-97b1-347a7f69a37a -->","topic":{"id":"3fa4323b-9014-5631-9410-a93ec7d2d0ac","topicId":"97ea63d1-8933-4fee-b1dd-7c6ac3ea2ab7","topicName":"Trichomoniasis","slug":"trichomoniasis","lastRevised":"Last revised in May 2020","chapters":[{"id":"e42d9436-b807-5262-a262-948244b520b5","fullItemName":"Summary","slug":"summary","subChapters":[]},{"id":"2b56e4dc-02e3-599e-a6bf-1a5413d868f0","fullItemName":"Have I got the right topic?","slug":"have-i-got-the-right-topic","subChapters":[]},{"id":"46f9586c-8974-558f-8ac1-6244bfd1883b","fullItemName":"How up-to-date is this topic?","slug":"how-up-to-date-is-this-topic","subChapters":[{"id":"65ddd7d3-15b0-53be-866f-5610e15e070d","slug":"changes","fullItemName":"Changes"},{"id":"c386cd94-aafd-5fe3-8a55-e502f9f681d1","slug":"update","fullItemName":"Update"}]},{"id":"a7c1505d-66b8-52d6-9b36-239f3eadfed0","fullItemName":"Goals and outcome measures","slug":"goals-outcome-measures","subChapters":[{"id":"c0dae047-42fb-5e25-9862-8967f319e9ee","slug":"goals","fullItemName":"Goals"},{"id":"a4744067-6bed-5f73-8911-66c7ff78570c","slug":"outcome-measures","fullItemName":"Outcome measures"},{"id":"89cbccbf-01cf-5343-bfb7-bad7760a2ded","slug":"audit-criteria","fullItemName":"Audit criteria"},{"id":"8b5c3a47-9564-552f-83c2-64f8926bec29","slug":"qof-indicators","fullItemName":"QOF indicators"},{"id":"6cd42b4c-a956-560f-9c6c-a0e3521bbace","slug":"qipp-options-for-local-implementation","fullItemName":"QIPP - Options for local implementation"},{"id":"9f22fed3-714e-5abe-9a52-34870887e267","slug":"nice-quality-standards","fullItemName":"NICE quality standards"}]},{"id":"2ebe6cd7-4b6e-5541-9699-5f4e0af542fe","fullItemName":"Background information","slug":"background-information","subChapters":[{"id":"b4bf3870-e41e-51aa-8ea8-ce962d1735b8","slug":"definition","fullItemName":"Definition"},{"id":"9aec8640-ee39-5d2f-97df-a62f06464af5","slug":"prevalence","fullItemName":"Prevalence"},{"id":"82e41ac8-9c05-5599-bdc6-d1ea0a1ecf7a","slug":"complications","fullItemName":"Complications"}]},{"id":"d1509154-ef5a-52ae-9c75-a9b6bf3bd4bf","fullItemName":"Diagnosis","slug":"diagnosis","subChapters":[{"id":"7159a76b-b760-5ee5-8e00-afc991a5ecb9","slug":"diagnosis-women","fullItemName":"Diagnosis - women"},{"id":"159b50a4-88fe-5cf2-9af2-43893eeeec84","slug":"diagnosis-men","fullItemName":"Diagnosis - men"}]},{"id":"004f5906-27c9-56f0-a599-802d0bdffa7c","fullItemName":"Management","slug":"management","subChapters":[{"id":"1c2af37c-700d-5c7c-95ea-049cde93a7e1","slug":"management","fullItemName":"Scenario: Management"}]},{"id":"b06121d3-a41a-5e65-a720-76900da7e5e7","fullItemName":"Prescribing information","slug":"prescribing-information","subChapters":[{"id":"4c83875e-ed21-58f7-99f4-4a509deb53b5","slug":"metronidazole","fullItemName":"Metronidazole"},{"id":"cdff86f4-ac12-56d7-b196-c5f9af1eb880","slug":"tinidazole","fullItemName":"Tinidazole"}]},{"id":"9e19b288-e085-5577-8ad2-b0a504a27f7f","fullItemName":"Supporting evidence","slug":"supporting-evidence","subChapters":[]},{"id":"7ab5ef58-ff30-5498-8faa-115c4d60dd3f","fullItemName":"How this topic was developed","slug":"how-this-topic-was-developed","subChapters":[{"id":"11960892-2762-52d0-8fac-3c436e4d4738","slug":"search-strategy","fullItemName":"Search strategy"},{"id":"a0cf5333-25ca-5bf8-9b3b-547067cd8d5f","slug":"stakeholder-engagement","fullItemName":"Stakeholder engagement"},{"id":"d9ecf639-6f52-5f87-85be-f921ce43f237","slug":"evidence-exclusion-criteria","fullItemName":"Evidence exclusion criteria"},{"id":"24dfa3bf-b2cc-5ace-9f72-a47e822dd30a","slug":"organizational-behavioural-financial-barriers","fullItemName":"Organizational, behavioural and financial barriers"},{"id":"7c7dfdd9-03c3-520f-a183-13ce32d19151","slug":"declarations-of-interest","fullItemName":"Declarations of interest"}]},{"id":"c998f4ca-7088-5e78-95d0-67151407d497","fullItemName":"References","slug":"references","subChapters":[]}]},"parentChapter":{"id":"b06121d3-a41a-5e65-a720-76900da7e5e7","slug":"prescribing-information","fullItemName":"Prescribing information"},"subChapters":[{"id":"62070c07-f6d7-59ea-a834-6c2d6910aa0f","slug":"contraindications-cautions","fullItemName":"Contraindications and cautions","depth":3,"htmlHeader":"<!-- begin field 110b81a5-2ad4-45ab-a19d-e495d7f8b6e1 --><h3>What are the contraindications and cautions for tinidazole?</h3><!-- end field 110b81a5-2ad4-45ab-a19d-e495d7f8b6e1 -->","summary":"","htmlStringContent":"<!-- begin item 7c6c0c2d-392b-4954-b011-933af3a1394e --><!-- begin field c2227cc2-2232-4cf0-acc3-8aa9225a97dd --><ul><li><strong>Do not prescribe tinidazole </strong><strong>to people:</strong><ul><li>Who have, or have a history of, blood dyscrasias, although no persistent haematological abnormalities have been noted in clinical or animal studies.</li><li>With organic neurological disorders.</li><li>Pregnant women. The manufacturer advises that tinidazole is contraindicated in the first trimester of pregnancy and should only be used in the second and third trimesters when absolutely necessary.</li></ul></li></ul><p>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/trichomoniasis/references/\">ABPI, 2016</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/trichomoniasis/references/\">ABPI, 2020</a>]</p><!-- end field c2227cc2-2232-4cf0-acc3-8aa9225a97dd --><!-- end item 7c6c0c2d-392b-4954-b011-933af3a1394e -->","subChapters":[]},{"id":"25bb341a-9d0a-5870-8a02-cf085a3975c0","slug":"adverse-effects","fullItemName":"Adverse effects","depth":3,"htmlHeader":"<!-- begin field 7d719dfd-1721-4cc8-ab68-33cc5b5db8ce --><h3>What are the adverse effects of tinidazole?</h3><!-- end field 7d719dfd-1721-4cc8-ab68-33cc5b5db8ce -->","summary":"","htmlStringContent":"<!-- begin item ab501d88-7557-4e9f-a08c-140b8ab90d9d --><!-- begin field 858c93f8-f221-4666-99cf-a25a8578e446 --><ul><li><strong>Adverse effects of tinidazole are generally infrequent, mild, and self-limiting.</strong> </li><li><strong>Common or very common adverse effects include</strong> abdominal pain, allergic dermatitis, decreased appetite, diarrhoea, headache, nausea, pruritis, vertigo, and vomiting.</li><li><strong>Other adverse effects include:</strong><ul><li>Frequency not known — abnormal sensation, altered taste, angioedema, ataxia, chromaturia, convulsion, dizziness, drug hypersensitivity, dysgeusia, fatigue, flushing, glossitis, leucopenia, oral disorders, peripheral neuropathy, pyrexia, seizure, stomatitis, tongue discolouration, urine discolouration, and urticaria.</li></ul></li></ul><p>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/trichomoniasis/references/\">ABPI, 2016</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/trichomoniasis/references/\">Joint Formulary Committee, 2019</a>]</p><!-- end field 858c93f8-f221-4666-99cf-a25a8578e446 --><!-- end item ab501d88-7557-4e9f-a08c-140b8ab90d9d -->","subChapters":[]},{"id":"dc9699fe-9e1d-5fe5-8ed3-6c8e76bbab79","slug":"drug-interactions","fullItemName":"Drug interactions","depth":3,"htmlHeader":"<!-- begin field 6d7648cb-96a1-427b-857a-16156cf06a49 --><h3>What are the drug interactions with tinidazole?</h3><!-- end field 6d7648cb-96a1-427b-857a-16156cf06a49 -->","summary":"","htmlStringContent":"<!-- begin item 57c22772-e38d-4ca3-80d6-8814cff5b090 --><!-- begin field 1d630d9f-77e1-44f3-beaf-e4533d6830e4 --><ul><li><strong>Drug interactions associated with tinidazole include:</strong><ul><li><strong>Alcohol </strong>— some people taking tinidazole experience a disulfiram-like reaction with alcohol (flushing, increased respiratory rate, increased pulse rate, nausea, headache, and dizziness).<ul><li>Advise that alcohol should be avoided for the duration of tinidazole treatment and for 72 hours afterwards [<a class=\"bibliography-reference internal-reference\" href=\"/topics/trichomoniasis/references/\">BASHH, 2014</a>].</li></ul></li><li><strong>Warfarin</strong> — tinidazole is predicted to increase the anticoagulant effect of warfarin.<ul><li>Monitor the international normalized ratio (INR), and adjust the dose of warfarin if necessary.</li></ul></li></ul></li></ul><p>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/trichomoniasis/references/\">ABPI, 2016</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/trichomoniasis/references/\">Joint Formulary Committee, 2019</a>]</p><!-- end field 1d630d9f-77e1-44f3-beaf-e4533d6830e4 --><!-- end item 57c22772-e38d-4ca3-80d6-8814cff5b090 -->","subChapters":[]}]}}},"staticQueryHashes":["3666801979"]}